(AI) C3 Ai - NYSE
Sector: Technology | Industry: Software - Infrastructure | Exchange: NYSE (USA) | Market Cap: 1.384m USD | Total Return: -63.8% in 12m
Avg Turnover: 86.2M
Qual. Beats: 0
Rev. Trend: 22.5%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality
C3.ai, Inc. is a U.S.-based enterprise artificial intelligence software company headquartered in Redwood City, California. The firm was incorporated in 2009 under the name C3 IoT, Inc., rebranded to C3.ai in June 2019, and completed its IPO on the NYSE in December 2020 under the ticker AI. It is classified within the Information Technology sector under the GICS Systems Software sub-industry.
The company sells a portfolio of AI application suites and a development platform to enterprises and government agencies. Its offerings include the C3 Agentic AI platform for building and deploying enterprise AI applications, a CRM suite, generative AI products, and vertical-specific packages for healthcare, financial services, defense and intelligence, and state and local government. It also provides applications targeting asset performance, supply chain, and sustainability, including ESG and energy management tools.
C3.ai distributes its software primarily through a subscription-based enterprise model, working with hyperscale cloud providers and large consulting and industry partners. The company maintains strategic partnerships with Microsoft Azure, AWS, Google Cloud, McKinsey & Company, Baker Hughes, and Booz Allen, and has an alliance with SMX Group for secure-environment deployments. Enterprise AI software vendors typically generate recurring revenue through multi-year cloud or licensed subscriptions sold to large corporate and public-sector customers, which can produce uneven revenue recognition tied to contract timing.
- Enterprise AI platform demand accelerates subscription revenue growth
- Microsoft Azure and AWS cloud partnerships expand deal pipeline
- Government defense AI contracts grow on rising federal spending
| Net Income: -470.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.23 > 0.02 and ΔFCF/TA -19.03 > 1.0 |
| NWC/Revenue: 240.3% < 20% (prev 198.5%; Δ 41.78% < -1%) |
| CFO/TA -0.23 > 3% & CFO -188.8m > Net Income -470.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (146.2m) vs 12m ago 9.75% < -2% |
| Gross Margin: 30.92% > 18% (prev 60.62%; Δ -29.70% > 0.5%) |
| Asset Turnover: 27.17% > 50% (prev 37.92%; Δ -10.75% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.74 (Total Current Assets 708.0m - Total Current Liabilities 106.6m) / Total Assets 816.3m |
| B: -2.27 (Retained Earnings -1.85b / Total Assets 816.3m) |
| C: -0.53 (EBIT TTM -487.7m / Avg Total Assets 921.1m) |
| D: 4.02 (Book Value of Equity 653.8m / Total Liabilities 162.5m) |
| Altman-Z'' = -1.89 = D |
| DSRI: 1.14 (Receivables 100.5m/137.2m, Revenue 250.3m/389.1m) |
| GMI: 1.96 (GM 60.62% / 30.92%) |
| AQI: 1.23 (AQ_t 0.05 / AQ_t-1 0.04) |
| SGI: 0.64 (Revenue 250.3m / 389.1m) |
| TATA: -0.34 (NI -470.4m - CFO -188.8m) / TA 816.3m) |
| Beneish M = -2.20 (Cap -4..+1) = BB |
As of June 29, 2026, the stock is trading at USD 8.90 with a total of 4,755,350 shares traded. Over the past week, the price has changed by -13.59%, over one month by -12.92%, over three months by +14.25% and over the past year by -63.78%.
Current recommended Stop Loss: 7.60 (which is 14.6% or 1.9 ATR below the current price).
C3 Ai has received a consensus analysts rating of 2.93. Therefore, it is recommended to hold AI.
- StrongBuy: 3
- Buy: 1
- Hold: 6
- Sell: 2
- StrongSell: 3
| Analysts Target Price | 8.8 | -0.9% |
P/S = 5.5281
P/B = 2.1162
Revenue TTM = 250.3m USD
EBIT TTM = -487.7m USD
EBITDA TTM = -474.1m USD
Long Term Debt = unknown (none)
Short Term Debt = 5.37m USD (from shortTermDebt, two quarters ago)
Debt = 5.37m USD (from shortLongTermDebtTotal, two quarters ago) (leases 5.58m already included)
Net Debt = -570.1m USD (calculated: Debt 5.37m - CCE 575.4m)
Enterprise Value = 813.4m USD (1.38b + Debt 5.37m - CCE 575.4m)
Interest Coverage Ratio = unknown (Ebit TTM -487.7m / Interest Expense TTM 0.0)
EV/FCF = -4.27x (Enterprise Value 813.4m / FCF TTM -190.7m)
FCF Yield = -23.44% (FCF TTM -190.7m / Enterprise Value 813.4m)
FCF Margin = -76.20% (FCF TTM -190.7m / Revenue TTM 250.3m)
Net Margin = -187.9% (Net Income TTM -470.4m / Revenue TTM 250.3m)
Gross Margin = 30.92% ((Revenue TTM 250.3m - Cost of Revenue TTM 172.9m) / Revenue TTM)
Gross Margin QoQ = 21.94% (prev 17.34%)
Tobins Q-Ratio = 1.00 (Enterprise Value 813.4m / Total Assets 816.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 5.37m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -385.3m (EBIT -487.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.64 (Total Current Assets 708.0m / Total Current Liabilities 106.6m)
Debt / Equity = 0.01 (Debt 5.37m / totalStockholderEquity, last quarter 653.8m)
Debt / EBITDA = 1.20 (negative EBITDA) (Net Debt -570.1m / EBITDA -474.1m)
Debt / FCF = 2.99 (negative FCF - burning cash) (Net Debt -570.1m / FCF TTM -190.7m)
Total Stockholder Equity = 736.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -51.07% (Net Income -470.4m / Total Assets 816.3m)
RoE = -63.91% (Net Income TTM -470.4m / Total Stockholder Equity 736.0m)
RoCE = -68.71% (EBIT -487.7m / Capital Employed (Total Assets 816.3m - Current Liab 106.6m))
RoIC = -55.26% (negative operating profit) (NOPAT -385.3m / Invested Capital 697.2m)
WACC = 12.17% (E(1.38b)/V(1.39b) * Re(12.22%) + D(5.37m)/V(1.39b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 8.99%
[DCF] Fair Price = unknown (Cash Flow -190.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.34 | # QB: 0
Revenue Correlation: 22.47 | Revenue CAGR: 3.44% | SUE: 0.12 | # QB: 0
EPS current Quarter (2026-07-31): EPS=-0.25 | Chg30d=N/A | Revisions=+25% | Analysts=14
EPS next Quarter (2026-10-31): EPS=-0.22 | Chg30d=N/A | Revisions=-7% | Analysts=14
EPS current Year (2027-04-30): EPS=-0.79 | Chg30d=N/A | Revisions=+25% | GrowthEPS=+41.7% | GrowthRev=-10.4%
EPS next Year (2028-04-30): EPS=-0.45 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+42.8% | GrowthRev=+10.0%
[Analyst] Revisions Ratio: +25%